Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial (Q34634662)

3 August 2017

title

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial (English)

1 reference

3 August 2017

1 reference

2

Gerhard Ehninger

1 reference

3 August 2017

4

Martin Bornhäuser

1 reference

3 August 2017

3

Christian Thiede

1 reference

3 August 2017

6

Christoph Röllig

1 reference

3 August 2017

8

Markus Schaich

1 reference

Study Alliance Leukemia (SAL)

3 August 2017

9

object named as

Study Alliance Leukaemia (SAL)

1 reference

3 August 2017

1

Markus Pfirrmann

0 references

author name string

Markus Pfirrmann

1

1 reference

3 August 2017

Michael Kramer

5

1 reference

3 August 2017

Joerg Hasford

7

1 reference

3 August 2017

publication date

22 December 2011

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

207-214

1 reference

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Optimal induction and post-remission therapy for AML in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Re: Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Cytogenetics in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Dangers of using "optimal" cutpoints in the evaluation of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Clinical trial designs for predictive marker validation in cancer treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Cytarabine dose for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970326-6

7 January 2021

10.1016/S1470-2045(11)70326-6

Identifiers

DOI

1 reference

3 August 2017

1 reference